{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-024661","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.528525+00:00","generated_at":"2026-06-01T03:05:02.059745+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Provectus shareholders approve reverse stock split authorization and other proposals at annual meeting","bullets":["All six proposals passed at June 20, 2024 annual meeting; directors elected with >96% votes cast.","Reverse stock split (1:10 to 1:50) authorized with 302.9M for (92.4%); authorized share reduction also approved.","Advisory vote on executive compensation passed with 202.8M for (96.6%); broker non-votes 115.0M.","Marcum LLP ratified as auditor for 2024 with 325.7M for (99.6%); no broker non-votes.","2024 Equity Compensation Plan approved with 198.3M for (94.0%); broker non-votes 115.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-024661","json":"https://secwatch.observer/filing/0001493152-24-024661.json","markdown":"https://secwatch.observer/filing/0001493152-24-024661.md","text":"https://secwatch.observer/filing/0001493152-24-024661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315224024661/0001493152-24-024661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315224024661/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:05:02.059745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}